| Literature DB >> 34591251 |
Hiroko Hirano1, Tomomi Ueda1, Hirohiko Tani2, Kenzo Kosaka2, Eiji Nakatani3,4, Philip Hawke5, Kiyoshi Mori6,7,8,9, Noriko Mori10.
Abstract
INTRODUCTION: Average dialysis vintage in Japan is among the longest in the world, providing a unique opportunity to characterize pregnancy under conditions of long dialysis vintage. In 2017, we carried out a nationwide survey following up on a similar survey in 1996, in which we investigated the prevalence and outcomes of pregnancy in women undergoing dialysis and assessed risk factors associated with neonatal and maternal complications.Entities:
Keywords: Complication; Delivery; Dialysis; Pregnancy; Preterm
Mesh:
Year: 2021 PMID: 34591251 PMCID: PMC8494660 DOI: 10.1007/s40620-021-01146-3
Source DB: PubMed Journal: J Nephrol ISSN: 1121-8428 Impact factor: 3.902
Fig. 1Outcomes of pregnancy in women undergoing hemodialysis in Japan, and association between birth weight, gestational age and neonatal complication. Comparison between the current study (a) and the previous study (b) is shown in pie charts. b was reproduced and modified from Toma et al. [8] by permission. c The gestational ages and birth weights of 14 live births in this study were tightly associated (P < 0.001, R = 0.94). The presence or absence of neonatal complications is indicated by black (n = 3) and white dots (n = 11), respectively. Japanese reference values (mean, ± 1.5 SD, and ± 2.0 SD) [12] and case numbers are also shown
Maternal characteristics, outcome of pregnancy and neonatal complications in pregnancy on hemodialysis
| Age at dialysis initiation/conception (years) | Dialysis vintage (years) | Cause of ESRD | cHT | sAlb (mg/dL) | Maternal complication | Hospitalization (weeks)/delivery | Reason for CS | Outcome | GA (weeks) | BW (g) | BW (SD) | Neonatal complication | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 20/21 | 0.8 | Alport | 2.9 | None | – | – | S. abortion | – | – | – | ||
| 2 | 24/26 | 2.4 | PKD | 3.7 | None | 37/CS | Recommended by a doctor | Surviving | 37 + 5 | 2562 | − 1.0 | None | |
| 3 | 29/30 | 0.8 | DN | + | 3.8 | HDP | – | – | S. abortion | – | – | – | |
| 4 | 17/32 | 15.1 | Alport | 3.6 | None | 23/CS | NRFS | Surviving | 27 + 6 | 1048 | − 1.2 | None | |
| 5 | 12/32 | 20.5 | NS | 3.2 | HDP (sHT), cervical insufficiency, preterm labor | 19/V | – | Surviving | 25 + 1 | 733 | − 1.1 | RDS, rickets | |
| 6 P1 | 30/33 | 2.8 | CGN | + | 3.2 | HDP | 20/CS | FGR | Surviving | 27 + 0 | 555 | − 3.9 | Retinopaty, rickets, ASD, VSD |
| 6 P2 | 30/34 | 4.3 | + | 3.1 | HDP | 29/CS | After CS | Surviving | 37 + 3 | 2038 | − 2.4 | None | |
| 6 P3 | 30/36 | 5.8 | + | 3.2 | HDP (sHT) | 32/CS | After CS | Surviving | 36 + 2 | 1750 | − 3.0 | None | |
| 7 | 26/35 | 9.1 | PurpN | 3.9 | Cervical insufficiency | 20/CS | NRFS | Surviving | 37 + 5 | 2520 | − 1.1 | None | |
| 8 | 28/35 | 7.4 | InterstN | 3.6 | None | 38/V | – | Surviving | 38 + 0 | 2788 | − 0.4 | None | |
| 9 P1 | 22/35 | 12.6 | IgAN | 3.4 | None | – | – | S. abortion | – | – | – | ||
| 9 P2 | 22/38 | 15.0 | 3.7 | None | – | – | S. abortion | – | – | – | |||
| 9 P3 | 22/38 | 15.1 | 3.6 | HDP | 30/V | – | Surviving | 38 + 3 | 2490 | − 1.5 | None | ||
| 10 | 35/38 | 3.4 | DN | + | 3.7 | HDP (sHT) | 20/CS | PROM, sHT | Surviving | 36 + 6 | 2303 | − 1.4 | None |
| 11 | 17/39 | 21.8 | MPGN | 3.2 | Total placenta previa, preterm labor | 22/CS | Total placenta previa, placental abruption | Surviving | 31 + 5 | 1564 | − 1.4 | RDS, cerebral palsy, epilepsy, neonatal jaundice, primary glaucoma | |
| 12 | 25/40 | 15.2 | ReflN | 3.3 | HDP (sHT), preterm labor | 22/V | – | Surviving | 31 + 6 | 1728 | − 0.7 | None | |
| 13 | 39/40 | 1.0 | PKD | 3.7 | None | – | – | E. abortion | – | – | – | ||
| 14 | 32/40 | 7.7 | DN | 3.3 | HDP, cervical insufficiency, ileus, preterm labor | 20/CS | Ileus | Surviving | 33 + 6 | 2138 | − 0.4 | None | |
| 15 | 38/40 | 2.3 | DN | + | 3.4 | HDP (sHT), cervical insufficiency, preterm labor | 21/CS | NRFS | Surviving | 32 + 1 | 1720 | – 0.7 | None |
cHT chronic hypertension at pregnancy start, sAlb serum albumin at the first trimester, CS cesarean section, GA gestational age shown as weeks + days, BW birth weight, P1–P3 the first, second and third pregnancy, Alport Alport syndrome, PKD polycystic kidney disease, IgAN IgA nephropathy, DN diabetic nephropathy, MPGN membranoproliferative glomerulonephritis, PurpN purpura nephritis, Refl Reflux nephropathy, NS nephrotic syndrome, CGN chronic glomerulonephritis, InterstN interstitial nephritis, V vaginal delivery, HDP, hypertensive disorders of pregnancy; sHT, severe hypertension during pregnancy; NRFS non-reassuring fetal status, FGR fetal growth restriction, PROM pre-mature rupture of membranes, Surviving surviving infant, S. abortion spontaneous abortion, E. abortion elective abortion, RDS respiratory distress syndrome, ASD atrial septal defect, VSD ventricular septal defect
Comparison of biochemistry, anthropometry findings and dialysis prescription in each trimester between preterm and full-term deliveries
| 1st trimester | 2nd trimester | 3rd trimester | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Preterm | Full-term | Preterm | Full-term | Preterm | Full-term | ||||
| Number | 9 | 5 | 9 | 5 | 5 | 5 | |||
| Age (years) | 36.7 ± 3.5 | 33.6 ± 4.5 | 0.18 | ||||||
| Dialysis vintage (years) | 10.5 ± 7.7 | 7.6 ± 4.9 | 0.47 | ||||||
| Biochemical parameters | |||||||||
| Timing of examination (weeks)a | 13 ± 1 | 12 ± 3 | 0.49 | 21 ± 1 | 21 ± 1 | 0.35 | 33 ± 2 | 32 ± 2 | 0.70 |
| Blood urea nitrogen (mg/dL) | 45 ± 22 | 56 ± 11 | 0.29 | 38 ± 7 | 50 ± 14 | 0.053 | 34 ± 16 | 24 ± 10 | 0.26 |
| Creatinine (mg/dL) | 8.7 ± 2.5 | 9.7 ± 1.9 | 0.44 | 7.4 ± 1.0 | 9.0 ± 2.6 | 0.12 | 6.4 ± 2.7 | 5.8 ± 1.9 | 0.69 |
| Albumin (g/dL) | 3.3 ± 0.2 | 3.6 ± 0.3 | 0.09 | 3.1 ± 0.4 | 3.3 ± 0.2 | 0.18 | 2.7 ± 0.4 | 2.9 ± 0.1 | 0.37 |
| Potassium (mEq/L) | 4.3 ± 0.6 | 4.6 ± 0.9 | 0.50 | 4.1 ± 0.4 | 4.5 ± 0.6 | 0.18 | 3.9 ± 0.6 | 3.9 ± 0.7 | 0.88 |
| Calcium (mg/dL) | 8.8 ± 0.6 | 9.1 ± 0.6 | 0.41 | 9.1 ± 0.5 | 9.2 ± 0.2 | 0.54 | 8.7 ± 0.7 | 9.1 ± 0.6 | 0.29 |
| Phosphate (mg/dL) | 4.5 ± 1.8 | 5.2 ± 1.4 | 0.43 | 4.2 ± 1.0 | 3.9 ± 0.8 | 0.33 | 3.8 ± 1.5 | 3.6 ± 1.0 | 0.88 |
| Hemoglobin (g/dL) | 9.7 ± 0.9 | 10.0 ± 0.8 | 0.48 | 9.8 ± 1.7 | 10.0 ± 1.5 | 0.71 | 11.0 ± 1.5 | 9.8 ± 0.4 | 0.12 |
| Blood pressure and dry weight | |||||||||
| Timing of examination (weeks)a | 13 ± 1 | 12 ± 3 | 0.49 | 20 ± 3 | 21 ± 1 | 0.33 | 33 ± 2 | 32 ± 2 | 0.70 |
| Systolic blood pressure (mmHg) | 128 ± 32 | 122 ± 26 | 0.71 | 136 ± 29 | 117 ± 17 | 0.21 | 141 ± 21 | 115 ± 15 | 0.0496 |
| Diastolic blood pressure (mmHg) | 75 ± 16 | 72 ± 20 | 0.71 | 79 ± 21 | 69 ± 10 | 0.36 | 90 ± 12 | 68 ± 10 | 0.013 |
| Dry weight (kg) | 58.6 ± 10.8 | 60.6 ± 12.0 | 0.76 | 60.3 ± 11.4 | 62.0 ± 11.7 | 0.80 | 63.3 ± 12.8 | 65.6 ± 11.9 | 0.78 |
| Dialysis prescription | |||||||||
| Dialysis time (hour/week) | 19.8 ± 4.9 | 20.5 ± 9.9 | 0.86 | 22.5 ± 3.7 | 22.9 ± 8.7 | 0.91 | 24.8 ± 5.0 | 27.8 ± 5.2 | 0.38 |
| Frequency (times/week) | 4.2 ± 0.8 | 4.4 ± 1.3 | 0.76 | 5.1 ± 0.9 | 4.8 ± 1.3 | 0.67 | 5.4 ± 0.5 | 5.8 ± 0.4 | 0.24 |
aGestational weeks
Nationwide surveys concerning pregnancy on dialysis
| References | First author | Country | Study period | Target population (cases) | Target age (years) | Mean age at pregnancy (years) | Mean dialysis vintage (years) | Pregnancy (times/patients) | Pregnancy rate (PTPY) | Surviving infant ratea (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| AJKD 1998 [ | Okundaye | USA | 1992–1995 | 6230 HD + PD | 14–44 | ND | 1 to 5 | 135/ND | > 5.5 | 40 |
| AJKD 1998 [ | Bagon | Beigium | 1975–1996 | 1472 HD + PD | 18–44 | 28.0 ± 3.2 | 3.0 | 15/14 | 3.3 | 50 |
| Nephrology 2013 [ | Shahir | AU/NZ | 1966–2008 | 7796 HD + PD | 15–49 | 30.7 | 4.0 | 49/ND | 2.1 | 79 |
| JASN 2014 [ | Hladunewich | USA | 1990–2011 | ND, HD | ND | 27 ± 6 | 1.5 | 70/ND | ND | 53 |
| JASN 2014 [ | Hladunewich | Canada | 2000–2013 | ND, HD | ND | 34 ± 4 | 3.4 | 22/17 | ND | 83 |
| JASN 2019 [ | Shah | USA | 2005–2013 | 47,555 HD + PD | 15–44 | 29 ± 6 | < 1 | 2352b/ND | 17.8c | 39 |
| AJKD 2020 [ | Oliverio | USA | 2002–2015 | 12,382 HD | 18–44 | 30.6 | 4.4 | ND/664b | (2.1–3.6)d | ND |
| Tsubasa | Hirano | Japan | 2012–2016 | 1992 HD | 15–44 | 34.6 ± 5.7 | 8.4 | 25/20 | 2.5e | 78 |
PTPY per thousand patient-years, HD hemodialysis, PD peritoneal dialysis, AU/NZ Australia and New Zealand, ND not described
aAmong pregnant patients on dialysis, excluding unknown outcomes
bThe study used administrative claim data, and may not be comparable to other survey-based cohort studies
cMore than half of patients were on dialysis for less than a year at study entry, which should have affected pregnancy rate in the study
dDelivery rate (pregnancy rate was not described)
eAssuming that all patients received dialysis for 5 full years